Novo Nordisk A/S (NYSE:NVO) Stock Price Down 0.3%

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s stock price traded down 0.3% during trading on Tuesday . The stock traded as low as $121.79 and last traded at $123.57. 1,246,042 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 4,908,507 shares. The stock had previously closed at $123.90.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday. They issued an "outperform" rating and a $163.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, April 1st. UBS Group began coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a "neutral" rating on the stock. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Moderate Buy" and a consensus target price of $133.60.

Novo Nordisk A/S Trading Down 0.4 %

The firm has a market cap of $553.99 billion, a P/E ratio of 45.68, a P/E/G ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The firm has a fifty day moving average of $126.04 and a 200-day moving average of $110.09.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.33 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a $0.664 dividend. This is a boost from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 49.17%.

Institutional Trading of Novo Nordisk A/S

Large investors have recently added to or reduced their stakes in the business. Westside Investment Management Inc. grew its holdings in shares of Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company's stock worth $130,000 after acquiring an additional 649 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth $2,408,000. Lazard Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 182.2% in the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company's stock worth $135,883,000 after buying an additional 964,640 shares during the period. Benedict Financial Advisors Inc. boosted its position in shares of Novo Nordisk A/S by 94.0% in the third quarter. Benedict Financial Advisors Inc. now owns 44,292 shares of the company's stock worth $4,028,000 after buying an additional 21,457 shares during the period. Finally, CENTRAL TRUST Co boosted its position in shares of Novo Nordisk A/S by 111.6% in the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company's stock worth $546,000 after buying an additional 3,166 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.